Severe multiorganic flare of systemic lupus erythematosus successfully treated with rituximab and cyclophosphamide avoiding high doses of prednisone.
- Published in:
- 2014
- By:
- Publication type:
- Case Study
Works matching IS 09612033 AND DT 2014 AND VI 23 AND IP 3
Results: 14
1
2
Lung, liver, prostate, bladder malignancies risk in systemic lupus erythematosus: evidence from a meta-analysis.
- Published in:
- Lupus, 2014, v. 23, n. 3, p. 284, doi. 10.1177/0961203313520060
- By:
- Publication type:
- Article
3
Polypoidal choroidal vasculopathy and systemic lupus erythematosus.
- Published in:
- 2014
- By:
- Publication type:
- Case Study
4
Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy.
- Published in:
- Lupus, 2014, v. 23, n. 3, p. 225, doi. 10.1177/0961203313519159
- By:
- Publication type:
- Article
5
Mycophenolate mofetil in the treatment of SLE and systemic vasculitis: experience at a single university center.
- Published in:
- Lupus, 2014, v. 23, n. 3, p. 299, doi. 10.1177/0961203313519158
- By:
- Publication type:
- Article
6
Associations of clinical features and prognosis with age at disease onset in patients with systemic lupus erythematosus.
- Published in:
- Lupus, 2014, v. 23, n. 3, p. 327, doi. 10.1177/0961203313513508
- By:
- Publication type:
- Article
7
Simultaneous changes in serum HMGB1 and IFN-α levels and in LAIR-1 expression on plasmatoid dendritic cells of patients with juvenile SLE.. New therapeutic options?
- Published in:
- Lupus, 2014, v. 23, n. 3, p. 305, doi. 10.1177/0961203313519157
- By:
- Publication type:
- Article
8
Synergistic effects of BuChE non-UU phenotype and paraoxonase (PON1) 55 M allele on the risk of systemic lupus erythematosus: influence on lipid and lipoprotein metabolism and oxidative stress, preliminary report.
- Published in:
- Lupus, 2014, v. 23, n. 3, p. 263, doi. 10.1177/0961203313518622
- By:
- Publication type:
- Article
9
The cost of care of systemic lupus erythematosus (SLE) in the UK: annual direct costs for adult SLE patients with active autoantibody-positive disease.
- Published in:
- Lupus, 2014, v. 23, n. 3, p. 273, doi. 10.1177/0961203313517407
- By:
- Publication type:
- Article
10
Extremely hypotrophic newborn of mother with systemic lupus erythematosus and antiphospholipid syndrome.
- Published in:
- Lupus, 2014, v. 23, n. 3, p. 313, doi. 10.1177/0961203313517406
- By:
- Publication type:
- Article
11
Circulating FABP4 is a marker of metabolic and cardiovascular risk in SLE patients.
- Published in:
- Lupus, 2014, v. 23, n. 3, p. 245, doi. 10.1177/0961203313517405
- By:
- Publication type:
- Article
12
Podocyte injury in pure membranous and proliferative lupus nephritis: distinct underlying mechanisms of proteinuria?
- Published in:
- Lupus, 2014, v. 23, n. 3, p. 255, doi. 10.1177/0961203313517152
- By:
- Publication type:
- Article
13
Prediction of subclinical atherosclerosis by serum osteoprotegerin in premenopausal women with systemic lupus erythematous: correlation of osteoprotegerin with monocyte chemotactic protein-1.
- Published in:
- Lupus, 2014, v. 23, n. 3, p. 236, doi. 10.1177/0961203313517151
- By:
- Publication type:
- Article
14
A surge in anti-dsDNA titer predicts a severe lupus flare within six months.
- Published in:
- Lupus, 2014, v. 23, n. 3, p. 293, doi. 10.1177/0961203313515763
- By:
- Publication type:
- Article